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Abstract
Background: Consequences of sarcoidosis are wide ranging, 
and the symptom burden has a great impact on patients’ 
quality of life (QoL). However, the QoL of couples living with 
sarcoidosis has not yet been studied. Objectives: Our aim 
was to assess the QoL of couples living with sarcoidosis and 
to evaluate whether living with a partner with sarcoidosis 
influences the partner’s QoL. Furthermore, we aimed to as-
sess whether nonspecific symptoms (fatigue, cognitive fail-
ure, small fiber neuropathy (SFN)-related symptoms, depres-
sive symptoms, and state/trait anxiety) predict QoL of part-
ners as well as sarcoidosis patients. Method: Sarcoidosis 
outpatients, recruited at Maastricht University Medical Cen-
tre (n = 443), and their partners (n = 208) completed several 
questionnaires, including the World Health Organization 
QoL - BREF, Fatigue Assessment Scale, SFN screening list, and 
cognitive failure questionnaire. Results: QoL of the partners 
as well as the sarcoidosis patients was reduced compared 
with healthy controls, especially regarding the physical 
health domain. All nonspecific symptoms studied, as well as 
perceived social support, predicted one or more QoL do-
mains in the sarcoidosis patients, but these factors did not 
predict the QoL of their partners. Conclusions: The QoL of 
partners of sarcoidosis patients was reduced, although to a 
lesser extent than that of the patients. Although the nonspe-
cific symptoms and perceived social support were related to 
the patients’ QoL, this was not the case for the partners. In 
the management of sarcoidosis, it is important to focus not 
only on the patients but also on their partners.
© 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Sarcoidosis is a multisystem inflammatory disorder of 
unknown cause(s) that imposes a burden on patients’ 
lives [1]. It affects men and women all over the world, at 
a relatively young age [2]. In addition to the specific or-
gan-related symptoms, less specific disabling symptoms, 
including fatigue, cognitive failure, symptoms associated 
with small fiber neuropathy (SFN), and physical impair-
ments, may have a major influence on the daily activities 
and the social and professional lives of the patients. These 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-





symptoms can lead to stress, anxiety, depression, and so-
cial and physical limitations [3–8]. Moreover, sarcoidosis 
patients experience reduced work ability [9–11].
The impact of any disease depends on the patient’s 
disease perception and coping strategies. Various as-
pects of sarcoidosis, such as the often unpredictable and 
chronic nature of the disease [2], the uncertainty about 
the cause, and the broad range of frequently persistent 
symptoms may result in an aggravating influence on pa-
tients’ lives. Hence, living with a long-term disease like 
sarcoidosis significantly affects patients’ quality of life 
(QoL), with negative consequences for general health 
and social and psychosocial well-being. QoL is a concept 
that concerns someone’s evaluation of their functioning 
in a wide range of domains but always includes the phys-
ical, psychological, and social domains. Anxiety and de-
pressive symptoms are also common in patients with 
sarcoidosis and are associated with disease severity [6, 
7]. Previous QoL studies showed that the QoL of pa-
tients with sarcoidosis is predicted by fatigue, depressive 
symptoms, reduced exercise capacity, dyspnea, and ar-
thralgia [1, 4, 8, 12–16]. Recently, Moor et al. [17] dem-
onstrated that sarcoidosis leads to anxiety, psychological 
distress, and impaired well-being not only in the pa-
tients but also in their partners. Studies on the influence 
of other nonspecific symptoms and studies examining 
the impact of living with a partner with sarcoidosis are 
scarce.
Therefore, the aim of our study was to evaluate wheth-
er living with a partner suffering from sarcoidosis influ-
ences the QoL of that partner, as well as to evaluate the 
QoL of the patients themselves. Moreover, we aimed to 
assess whether nonspecific symptoms, including fatigue, 
cognitive failure, SFN-related symptoms, and psycholog-
ical factors including depressive symptoms and anxiety in 
sarcoidosis patients predict the QoL of partners and pa-
tients.
Material and Methods
Study Design and Subjects
We conducted a cross-sectional, prospective cohort study eval-
uating fatigue and QoL in sarcoidosis patients and their partners 
between 2007 and 2009. Data regarding fatigue in sarcoidosis pa-
tients were previously used in De Kleijn [18]. Data from the cur-
rent study regarding the QoL of sarcoidosis patients and their part-
ners were analyzed in 2018 and not reported previously. Patients 
(n = 588) evaluated and/or treated at the ILD Center of the Depart-
ment of Pulmonology of Maastricht University Medical Center, a 
tertiary referral center in The Netherlands, were asked to partici-
pate between September 2007 and July 2008. After inclusion of the 
patients, their partners (if they had a partner) were also asked to 
participate. Patients were all diagnosed with sarcoidosis based on 
the guidelines of the world association of sarcoidosis and other 
granulomatous disorders [2]. The Medical Ethics Committee of 
MUMC+ (07-4-015) approved the study protocol, and written in-
formed consent was obtained from all patients.
Procedure
Information about the study was sent by E-Mail (which every 
patient and/or partner asked to participate had access to), and pa-
tients as well as their partners were asked to complete and return 
an informed consent form if they were willing to participate. After 
having agreed to participate, they received the set of questionnaires 
and were asked to return the completed set to the hospital in an 
enclosed envelope.
The following characteristics were collected: gender and age 
(patients and partners) and time since diagnosis of sarcoidosis 
and  sarcoidosis treatment (patients). Patients completed several 
questionnaires: World Health Organization QoL-BREF (WHO-
QoL-BREF), Fatigue Assessment Scale (FAS), SFN Screening List 
(SFNSL), cognitive failure questionnaire (CFQ), state and trait 
anxiety inventory (STAI), Center for Epidemiological Studies De-
pression Scale (CES-D), and Perceived Social Support Scale (PSSS). 
The partners were asked to complete the WHOQoL-BREF, FAS, 
and CFQ.
Questionnaires
Questionnaire scores of patients and partners in the present 
study were compared with corresponding questionnaire scores of 
a healthy control sample (n = 62) recruited for a study by Marcel-
lis et al. [19]. These healthy controls were recruited in the same 
geographical area/institution and timeframe as our study sample. 
We used the raw data of this healthy control population.
Detailed descriptions of the questionnaires (WHOQoL-BREF, 
FAS, SFNSL, CFQ, STAI, CES-D, PSSS) can be found in the online 
supplementary material (for all online suppl. material, see www.
karger.com/doi/10.1159/000501657) [20–26].
Statistical Analysis
All statistical analyses were performed using SPSS version 24 
for Mac. The chi-square test, the independent-samples t test 
(partners vs. controls and patients vs. controls), and paired t tests 
(patients vs. partners) were used to test for statistically significant 
differences between patients, their partners, and controls. Hier-
archical linear regression analyses were used to assess the asso-
ciations between the scores for the various domains of the sar-
coidosis patients’ and partners’ WHOQoL-BREF and the sar-
coidosis patients’ fatigue (FAS), SFNSL, CFQ, CES-D, STAI, and 
PSSS. Adjustments were made for age, sex, treatment, and time 
since diagnosis in the analysis regarding patients and for age and 
sex in the analysis regarding partners. Since each WHOQoL-
BREF domain was analyzed by means of a separate regression 
model, a Bonferroni correction was used to reduce the risk of 
false-positive findings, by adjusting the significance level in these 
5 regression analyses from 0.05 to 0.01. Hence, within each of the 
10 WHOQoL-BREF regression models (5 for patients and 5 for 
partners), p values of < 0.01 were considered to indicate statistical 
significance. In view of this correction, we also reported 99% CIs 
(instead of the conventional 95% CIs) around the estimated re-
gression coefficients.
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In a post hoc analysis, we have performed a mediation analysis 
using the Baron and Kenny method [27]. A moderation analysis 
was performed by including the product of 2 mean-centered pre-
dictors in a regression analysis, on top of the main effects of these 
2 predictors.
Results
Three quarters of the approached sarcoidosis patient 
sample (443/588) agreed to participate, of whom 10 
were excluded from further analyses because they did 
not complete the main outcome measure QoL. Two-
hundred and eight partners decided to participate and 
completed the questionnaires. The sarcoidosis patients 
whose partners participated in the study (n = 208) did 
not differ from those without a partner or whose part-
ners did not participate (n = 225), except for age (Table 
1).
Table 1 summarizes the demographic and clinical 
data, and the questionnaire scores of the 433 included pa-
tients are summarized. The prevalence of the various 
nonspecific symptoms among the sarcoidosis patients 
and their partners is shown in Figure 1.
QoL Partners and Patients
Table 2 summarizes the characteristics and outcomes 
of the partners of the sarcoidosis patients and the sarcoid-
osis patients themselves as well as the comparison with 
healthy control subjects.
The overall QoL scores of the partners were lower than 
those of the healthy controls (p < 0.001). The QoL domain 
scores (Physical, Psychological, Social, Environment) 
were also lower for partners than for healthy controls.
The QoL of the sarcoidosis patients was significantly 
more impaired than that of their partners, overall as well 
as in the different domains (all p values < 0.001, except 
social relationships p = 0.002).
Table 1. Summary of the demographic and clinical characteristics of the sarcoidosis patient sample studied
Total sarcoidosis
sample (n = 433)
Sarcoidosis patients included
in partner analysis (n = 208)
Sarcoidosis patients excluded
from partner analysis (n = 225)
Male 233 (53.8) 108 (51.9) 126 (55.5)
Age, years 48±11.1 (19–79) 46.5±10.2 (27–79) 49.3±11.7 (19–78)*
Time since diagnosis, years 7.7±7.8 (0–65) 7.2±6.4 (0–44) 8.1±8.9 (0–65)
Medication
None 157 (36.3) 71 (34.1) 86 (37.9)
Prednisone 219 (50.6) 105 (50.5) 116 (51.1)
Methotrexate 74 (17.1) 38 (18.3) 36 (15.9)
TNF-α antagonists 38 (8.8) 21 (10.1) 17 (7.5)
FAS score 29.3±8.4 30.1±8.5 28.7±8.3
SFNSL score 29.9±15.6 24.8±15.8 23.1±15.4
CFQ score 36.6±16.1 43±17.1 34.8±16.1
STAI
State 11.6±3.7 11.5±3.5 11.6±3.8
Trait 40.6±7.7 40.6±7.7 40.6±7.7
CESD 14.2±9.7 14±9.5 14.5±9.9
PSSS 62.5±13.4 63.3±13.4 61.8±13.4
WHOQoL–BREF
Physical health 12.2±3.1 12.2±3 12.3±3.1
Psychological health 14.2±2.3 14.3±2.3 14.1±2.4
Social relationships 14.2±2.8 14.4±2.8 14.0±2.9
Environment 15.5±2.5 15.8±2.4 15.2±2.6
Overall QoL 6±1.6 6±1.6 6±1.6
Data are expressed as mean ± SD or range in parentheses if appropriate.
* Statistically significant: p = 0.01.
TNF, tumor necrosis factor; FAS, Fatigue Assessment Scale; SFNSL, Small Fiber Neuropathy Screening List; CFQ, Cognitive Failure 
Questionnaire; STAI, State and Trait Anxiety Inventory; CESD, Center for Epidemiological Studies-Depression Scale; PSSS, Perceived 





Associations of QoL of Partners and Sarcoidosis 
Patients
Hierarchical multiple linear regression analyses dem-
onstrated that, after adjustment for the covariates age and 
gender of the partner, none of the nonspecific symptoms 
(fatigue, SFN-associated symptoms, cognitive failure, 
state/trait anxiety, depressive symptoms, and perceived 
social support) of the patients, including their QoL, were 
associated with the overall QoL score and those for the 4 
QoL domains of their partners.
Hierarchical multiple linear regression analyses dem-
onstrated that, after adjustment for the covariates age, 
gender, and time since diagnosis and treatment, all non-
specific symptoms we studied, except momentary anxi-
ety, were associated with the overall QoL score and those 
for the 4 QoL domains of the sarcoidosis patients, pre-
dicting 32–63% of the variance (Table 3).
Depressive symptoms were negatively associated with 
the overall QoL score and those for all domains, except 
social relationships. Perceived social support was posi-
tively associated with all QoL domains, except physical 
health. Fatigue was negatively associated with the overall 
QoL score and those for the physical and psychological 
QoL domains. SFN-associated symptoms were negatively 
associated with the physical and environmental QoL do-
mains. Trait anxiety was negatively associated with the 
psychological and social QoL domains. Finally, cognitive 
problems were only negatively associated with the QoL 
domain of physical health, but this association was sub-
ject to a mediation effect (see below).











Subjects, n 208 208 62
Male 96 (46.2) 108 (51.9) 40 (64.5) 0.023 0.239 0.138
Age, years 46.2±11.3 (16–80) 46.5±10.2 (27–79) 46.4±9.9 (30–65) 0.622 0.900 0.763
Time since diagnosis, years NA 7.2±6.4 (0–44) NA
WHOQoL-BREF domains
Physical 16.6±2.1 12.2±3.0 18.0±1.5 4.47±3.5 <0.001 <0.001 <0.001
Psychological 15.7±2.0 14.3±2.3 17.0±1.9 1.29±2.7 <0.001 <0.001 <0.001
Social 15.2±2.6 14.4±2.8 17.3±2.4 0.73±3.2 <0.001 0.002 <0.001
Environment 16.7±2.0 15.8±2.4 17.7±1.6 0.95±2.7 <0.001 <0.001 <0.001
Overall 8.2±1.2 6.0±1.6 8.7±1.0 2.28±1.9 <0.001 <0.001 <0.001
FAS score 17.5±4.9 30.1±8.5 15.6±4.0 12.6±9.9 <0.001 <0.001 <0.001
CFQ total score 24.9±11.2 43.0±17.1 31.3±10.1 18.2±20.1 <0.001 <0.001 <0.001
Data are expressed as mean ± SD or range in parentheses if appropriate. 
* p values resulting from a paired t test testing for differences between the 2 groups.
NA, not applicable; WHOQoL-BREF, World Health Organization Quality of Life-BREF; FAS, Fatigue Assessment Scale; CFQ, cognitive failure 
questionnaire. 
SFN associated symptoms patients (SFNSL >11)
0 15 30
Patients or partners, %
45 60 75
Anxiety (STAI trait >40)
Depressive symptoms (CESD >16)
Fatigue partners (FAS >22 and ≤34)
Fatigue patients (FAS >22 and ≤34)
Extreme fatigue partners (FAS >34)
Extreme fatigue patients (FAS >34)
Cognitive failure partners (CFQ >43)




Fig. 1. Non-specific symptoms in the sar-
coidosis patients and their partners. * p < 
0.001. FAS, Fatigue Assessment Scale; SF-
NSL, small fiber neuropathy screening list; 
CFQ, cognitive failure questionnaire; 
STAI, state and trait anxiety inventory; 
CESD, center for epidemiological studies-
depression Scale.
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To simplify, overall QoL is predicted by fatigue and de-
pressive symptoms. The QoL domain physical health is 
predicted by fatigue, SFN-associated symptoms, depres-
sive symptoms, and cognitive failure. The QoL domain 
psychological health is predicted by fatigue, trait anxiety, 
depressive symptoms, and perceived social support. The 
QoL domain social relationships is predicted by trait anxi-
ety and perceived social support. And last, the QoL domain 
environment is predicted by SFN-associated symptoms, 
depressive symptoms, and perceived social support (Fig. 2).
Relative Importance of the QoL Predictors in Partners 
and Sarcoidosis Patients
The QoL predictors for partners were not significant 
and are therefore not described any further here.
As regards the patients, the predictors explained 62.9% 
of the variance in the physical health domain scores. This 
domain was best predicted by fatigue, followed by SFN-
associated symptoms, depressive symptoms, and cogni-
tive failure.
The predictors explained 61.9% of the variance in the 
psychological health domain. This domain was best pre-
Table 3. Predictors of the WHOQoL-BREF
Predictor WHOQoL–BREF
overall QoL score physical health psychological health social relationships environment
FAS –0.10* (–0.13 to –0.08)
β = –0.55
–0.21* (–0.26 to –0.17)
β = –0.59
–0.06* (–0.09 to –0.02)
β = –0.20
–0.03 (–0.08 to 0.03) –0.03 (–0.10 to 0.05)
SFNSL –0.01 (–0.02 to 0.01) –0.04* (–0.06 to –0.02)
β = –0.20
0.02 (0.00 to 0.03) –0.01 (–0.04 to 0.02) –0.03* (–0.06 to –0.01)
β = –0.18
CFQ 0.01 (0.00 to 0.03) 0.02* (0.00 to 0.05)
β = 0.12
0.00 (–0.02 to 0.01) 0.02 (–0.01 to 0.05) 0.01 (–0.02 to 0.03)
STAI Trait 0.00 (–0.04 to 0.04) 0.02 (–0.05 to 0.08) –0.10* (–0.15 to –0.05)
β = –0.32
–0.10* (–0.17 to -0.02)
β = –0.26
–0.03 (–0.10 to 0.05)
STAI State –0.03 (–0.10 to 0.04) –0.11 (–0.22 to 0.01) –0.06 (–0.15 to 0.03) 0.02 (–0.12 to 0.16) –0.02 (–0,16 to 0.12)
CESD –0.04* (–0.07 to –0.01)
β = –0.24
–0.06* (–0.11 to –0.01)
β = –0.17
–0.08* (–0.12 to –0.03)
β = –0.31
–0.06 (–0.13 to 0.00) –0.07* (–0.13 to –0.01)
β = –0.27
PSSS 0.00 (–0.01 to 0.01) 0.00 (–0.02 to 0.02) 0.02* (0.01 to 0.04)
β = 0.11
0.07* (0.05 to 0.10)
β = 0.34
0.03* (0.01 to 0.06)
β = 0.17
R2, % 51 63 62 42 32
* p < 0.01.
Unstandardized regression coefficients and their 99% CIs are shown. For significant effects, standardized regression coefficients are reported 
in bold face. R2 = Percentage of additionally explained variance of the model including predictors above and beyond the model with theoretically 
important covariates only. 
WHOQoL-BREF, World Health Organization Quality of Life-BREF; FAS, Fatigue Assessment Scale; SFNSL, Small Fiber Neuropathy 
Screening List; CFQ, Cognitive Failure Questionnaire; STAI, State and Trait Anxiety Inventory; CESD, Center for Epidemiological Studies-





















Fig. 2. Simplification of the effect of predictors on overall QoL 
and the 4 domains as presented in Table 3. CESD, Center for 
Epidemiological Studies-Depression Scale; CFQ, cognitive fail-
ure questionnaire; FAS, Fatigue Assessment Scale; PSSS, per-
ceived social support scale; QoL, quality of life; SFNSL, small 
fiber neuropathy screening list; STAI, state and trait anxiety in-






dicted by trait anxiety, depressive symptoms, fatigue, and 
perceived social support. Perceived social support had a 
positive effect on the psychological QoL, while the other 
variables had negative effects.
The predictors explained 41.7% of the variance in the 
social relationships domain. This domain was best pre-
dicted by trait anxiety and perceived social support. Per-
ceived social support had a positive effect on QoL, while 
trait anxiety had a negative effect.
The predictors explained 31.8% of the variance in the 
environment domain. This domain was best predicted by 
the depressive symptoms, SFN-associated symptoms, 
and perceived social support. Again, perceived social sup-
port had a positive effect on QoL, while depressive symp-
toms and SFN-associated symptoms had a negative effect.
The predictors explained 50.7% of the variance in the 
overall QoL score, and this was best predicted by fatigue 
and depressive symptoms.
Mediation Analysis
The results in Table 3 suggest that cognitive failure had 
a positive effect on QoL (unstandardized B 0.024), indi-
cating that patients with more cognitive failure had a 
higher physical QoL. Since cognitive failure has a great 
impact on the lives of sarcoidosis patients, and given that 
the present sample included mostly young patients with 
a busy social and working life, this finding was against our 
expectations. In regression models, a significant associa-
tion between a predictor and an outcome may in fact be 
explained by a third variable, such as a confounder, me-
diator, or moderator. Therefore, we inspected the partial 
and zero-order correlations between the physical domain 
of QoL and the predictors. The zero-order correlations 
showed that there was, as expected, a negative association 
between CFQ and physical QoL. However, after adjusting 
for the influence of other predictors (primarily fatigue 
and depressive symptoms), this negative association dis-
appeared through collinearity. Figure 3 shows 2 media-
tion models where fatigue and depressive symptoms, re-
spectively, mediate the association between cognitive fail-
ure and physical QoL. Indeed, the significant zero-order 
correlation between these 2 measures disappeared when 
the mediating effects of fatigue and depressive symptoms 
were included in the model (Fig. 3a, b). Furthermore, a 
moderation analysis showed a significant interaction ef-
fect between the CFQ and FAS as well as CESD on phys-
ical QoL (CFQ-FAS: β = 0.078, SE = 0.001, t = 2.182, p = 
0.03, respectively, CFQ-CESD: β = 0.176, SE = 0.001, t = 
3.795, p < 0.001). These results suggest that there may be 
multiple mechanisms underlying the relations between 
these variables.
Discussion
This is the first study to show that the QoL of couples 
where one of the partners suffers from sarcoidosis is re-
duced compared to that of healthy controls. Neither the 
B (excluding FAS) = –0.074 (–0.098, –0.049)*
B = –0.214 (–0.256, –0.171)*B = 0.260 (0.196, 0.324)*






B (excluding CESD) = –0.074 (–0.1, –0.048)*
B = –0.055 (–0.107, –0.002)*B = 0.288 (0.214, 0.363)*






Fig. 3. a Impact of the FAS score on the 
CFQ regression coefficient in predicting 
the QoL. b Impact of depressive symptoms 
score (CES-D Scale) on CFQ regression co-
efficient in predicting the QoL. * Statisti-
cally significant. WHOQoL, World Health 
Organization quality of life; FAS, Fatigue 
Assessment Scale; CFQ, cognitive failure 
questionnaire; CES-D, Center for Epide-
miological Studies-Depression; B, stan-
dardized regression coefficient.
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QoL nor nonspecific symptoms of the sarcoidosis pa-
tients predicted the QoL of the partners of the sarcoidosis 
patients we studied. Predictors of the QoL of the sarcoid-
osis patients themselves were fatigue, depressive symp-
toms, SFN-associated symptoms, cognitive failure, anxi-
ety, and perceived social support. All of these non-specif-
ic symptoms, except perceived social support, had a 
negative impact on various aspects of the QoL of the sar-
coidosis patients. This underlines the importance of de-
termining all these non-specific symptoms in sarcoidosis 
patients.
The importance of patient-centeredness in health-
care has grown over the years. So far, family involve-
ment and perspectives have infrequently been studied in 
sarcoidosis. A novel finding from our study is that part-
ners of sarcoidosis patients also had a lower QoL than 
healthy persons, but to a lesser extent than that of the 
sarcoidosis patients we studied. The QoL of the partners 
living with a sarcoidosis patient was mainly lower in the 
psychological and social domains. We did not study the 
perceived social support for partners, but one could 
speculate that partners have less perceived social sup-
port and often feel misunderstood by people in their en-
vironment because of the lack of awareness of sarcoid-
osis as a disease. Previous studies have shown a relation-
ship between social support and the QoL of partners of 
patients [28, 29]. This needs to be examined in future 
studies. They may also experience psychological dis-
tress, leading to anxiety [17], as sarcoidosis can be un-
predictable and they worry about the consequences re-
garding the future of the patient as well as their own 
future. There is a need for further studies into dyadic 
coping in sarcoidosis.
In line with other studies, we found a lower QoL for 
our sarcoidosis patient sample than for healthy controls, 
especially in the physical health domain, meaning that 
they feel less physically healthy than the healthy popula-
tion [13, 14, 16, 30]. Apart from major organ involve-
ment, sarcoidosis patients can be bothered with reduced 
muscle strength, loss of physical condition, pain, extreme 
fatigue, and SFN-associated symptoms [1, 31]. Psycho-
logical factors are pervasive and include anxiety, depres-
sive symptoms, and mental fatigue, including memory 
problems, lack of mental clarity, poor concentration, and 
inability to focus. These factors may not correspond with 
inflammatory disease activity nor respond to sarcoidosis 
treatment [1, 5]. The symptoms are disabling, persist after 
other signs of sarcoidosis activity have resolved, and ad-
versely impact on major life areas, including QoL and 
work ability [32, 33]. Tan et al. [34] did find that the more 
symptoms affecting the patient, the more it affected the 
partner’s QoL.
Depressive symptoms, anxiety, and cognitive failure 
have increasingly been reported in clinical practice as 
well as in studies [4, 6, 7, 35–38]. Depressive symptoms 
are a known predictor of QoL in sarcoidosis [4, 38]. A 
novel finding is that not only depressive symptoms but 
also trait anxiety and subjective cognitive failure predict-
ed QoL in our sarcoidosis sample. The association be-
tween cognitive failure and QoL disappeared when we 
included fatigue and depressive symptoms as mediators 
(Fig. 3a, b). This may imply multiple competing interpre-
tations. First, cognitive failure presumably results in 
more depressive symptoms or fatigue, which in turn re-
sults in a lower physical QoL. This is in line with a previ-
ous study by Hendriks et al. [5] who found that cognitive 
failure predicted fatigue. Alternatively, it could indicate 
that depressive symptoms or fatigue causally affect both 
cognitive failure and physical QoL. Since we also found 
significant moderating effects between cognitive failure 
and depressive symptoms as well as fatigue on physical 
QoL, there may also be a moderating mechanism under-
lying the associations between these variables. This hy-
pothesis was also supported by a previous study by our 
group in neurosarcoidosis patients, showing fatigue to be 
a strong predictor of cognitive impairment [39]. Studies 
in dialysis patients also found that depressive symptoms 
predicted cognitive impairment [40, 41]. As follow-up 
data were lacking in our study and cross-sectional studies 
generally have limitations with regard to establishing 
causality, the results have to be interpreted with some 
caution, and future follow-up studies are warranted to 
distinguish between these 2 interpretations for sarcoid-
osis patients.
To date, studies have shown a high prevalence of fa-
tigue [8, 12, 42–45] and SFN-associated symptoms [46, 
47] in sarcoidosis patients. In line with previous studies 
[13–15], our study found that sarcoidosis-associated fa-
tigue was negatively associated with overall QoL, as well 
as the physical and psychological QoL domains, indicat-
ing that these QoL domains tend to decrease as patient 
fatigue increases. Of the partners, only 15% experienced 
fatigue (mainly moderate; 30/31 partners) in comparison 
with 78% of the sarcoidosis patients. Whether the moder-
ate fatigue in a small proportion of partners might be 
caused by their own disabilities and/or health problems 
needs to be explored in future studies. In agreement with 
earlier studies, a substantial number of our sarcoidosis 
sample were suffering from SFN-associated symptoms 





to treat [48]. This causes a lot of uncertainty and frustra-
tion for those having to deal with these problems. The 
presence of SFN-associated symptoms was found to be 
negatively associated with the physical and environmen-
tal QoL domains, indicating that physical and environ-
mental QoL tends to decrease when patients experience 
more SFN-associated complaints. This could, at least 
partly, be explained by the fact that patients feel they are 
not being taken seriously by relatives and friends and ex-
perience misunderstanding because of lack of awareness 
of sarcoidosis and SFN.
The clinical course of sarcoidosis is highly variable, 
ranging from spontaneous resolution to disabling chron-
ic disease with various manifestations [49]. In our cohort, 
no relation was found between the various manifestations 
and QoL (data not shown), stressing the importance of 
assessing not only the organs affected by sarcoidosis but 
also the nonspecific symptoms [5, 31].
All of the above-mentioned nonspecific symptoms are 
not visible in sarcoidosis patients, making it difficult for 
them to get acknowledged, leading to feelings of misun-
derstanding in many patients and even their partners 
[17]. Sarcoidosis patients have reported that QoL is the 
most important outcome of their treatment and of care, 
more important than radiographs, pulmonary function 
tests, and blood tests [32]. Most patients would like to see 
more attention and support for their psychological prob-
lems [17, 50]. We also found that patients with better sup-
port show a better QoL in all domains, except for physical 
health. Moreover, although it was beyond the scope of 
this study, it would be interesting to evaluate how not liv-
ing with a partner might influence the QoL of sarcoidosis 
patients.
Sarcoidosis clinicians usually work in a multidisci-
plinary team. Our results underline the importance of a 
multidisciplinary approach assessing not only organ in-
volvement but also any symptoms (organ-related or non-
organ-related) and of using a holistic approach with at-
tention to psychological support, for both patients and 
their partners. One of the possible interventions could be 
mindfulness-based exercise interventions, which have 
been found to reduce psychological symptoms and fa-
tigue [51].
A limitation of the present study was that all patients 
were recruited in a tertiary referral center. This could 
have led to selection bias, since it is the more complex 
patients (in terms of affected organs and symptoms) 
who are often referred to tertiary referral centers. Hence, 
our results may not be generalizable to all sarcoidosis 
patients. However, our results are comparable with 
those of other QoL studies in sarcoidosis patient sam-
ples. Another limitation is that not all partners of the 
patients with sarcoidosis seen at the outpatient clinic 
participated in this study, and some patients did not 
have a partner. However, the sample of sarcoidosis pa-
tients whose partners participated did not differ from 
those without a partner or with a partner who did not 
participate in our study (except for age). Unfortunately, 
information on the medical health status of the partners 
was not collected in this study. It is tempting to speculate 
that this explains for the lower QoL of the partners com-
pared to healthy controls. Though, the QoL of partners 
was higher than the QoL of the sarcoidosis patients. 
Strikingly, however, no relation was found between the 
QoL of the partners and the burden of the sarcoidosis 
experienced by the patients themselves indicating that 
this does not have an impact on the QoL of their part-
ners. One final limitation was the fact that we did not 
have a matched control group and that the sample of 
healthy controls used in our study was rather small, 
which might increase the influence of sampling error on 
the estimated statistics in the control sample. Our con-
trol group did consist of persons living in the same geo-
graphical area/institution and timeframe and was previ-
ously used by our group for similar comparisons in pre-
vious studies [13, 19, 44].
Conclusion
Couples living with sarcoidosis have a lower QoL than 
healthy controls. Sarcoidosis patients often struggle with 
fatigue, SFN-associated symptoms, anxiety, depressive 
symptoms, and memory and concentration problems. All 
these symptoms have a negative impact on the QoL of 
patients, but not on that of their partners. Although these 
factors pose challenges for objective assessment, they are 
recognized illness-related symptoms meriting formal 
consideration with validated instruments. Perceived so-
cial support positively impacts on the QoL. Further stud-
ies are needed to investigate whether offering psychoso-
cial support at the outpatient clinic for sarcoidosis pa-
tients as well as their partners would lead to better coping 
strategies and improve QoL for both of them.
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